Thursday, January 12, 2017 3:44:33 AM
Mylan/ the epi-pen is an easy whipping boy, but given the increasing focus on cost effective meds, it wouldn't be too surprising for other insurances to play this same game, and to expand it into other medicines.
Given the cost involved with inexorable annual substantial increases, its not hard to imagine they might eventually say the same 'generic only' for 20mg and then 40mg Copaxone -- and then the biosimilars . . .
MTB
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM